Another probe, 68Ga-NOTA-RTD01, featuring improved pharmacokinetics targeting Trop2, was further developed and demonstrated advantageous diagnostic capabilities in preclinical pancreatic cancer models 95. Here, TACSTD2 is linked to familial pancreatic carcinoma.